Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
James Godfrey(City of Hope), Lihua E. Budde(City Of Hope National Medical Center), Joo Y. Song(City Of Hope National Medical Center), Alex F. Herrera(City of Hope), Bihong T. Chen(City Of Hope National Medical Center), Avyakta Kallam(City Of Hope National Medical Center), Lucy Ghoda(City Of Hope National Medical Center), John H. Baird(City Of Hope National Medical Center), Lei Gao(First Affiliated Hospital of Xi'an Jiaotong University), Guido Marcucci(City of Hope), Alexey V. Danilov(City of Hope), Stacy Pak(City Of Hope National Medical Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Stéphanie Vauléon(Roche (Switzerland)), Brian Lee(City Of Hope National Medical Center), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 50
Related Papers
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560